Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TMC Bets Dosing Convenience, Field Force Synergies Will Help Oritavancin Prosper

This article was originally published in The Pink Sheet Daily

Executive Summary

The Medicines Co. held an analyst meeting Oct. 9 in large measure to broadcast the progress it has made diversifying away from its current chief revenue generator, the cardiovascular drug Angiomax. It’s betting that its first foray into antibiotics, the IV-administered drug oritavancin, will best competition because of dosing advantages, efficacy, and the sponsor’s deep expertise in the tumultuous hospital market

You may also be interested in...



Mirror, Mirror: Long-acting Antibiotics Dalbavancin, Oritavancin Emerging With Similar Profiles

Full results for Durata’s dalbavancin and The Medicine’s Co.’s oritavancin – both lipoglycopeptides – suggest the mode of administration is likely to become a key differentiating factor if the drugs are approved.

Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?

Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.

Ketamine May Shake Up The Treatment Of Major Depression

Pharmas have shied away from the challenging antidepressant market in recent years, but two late-stage ketamine-like candidates are leading the pack of novel agents in development.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel